Accelerating paediatric formulation development through smart design and predictive science
Lead Participant:
ASTRAZENECA UK LIMITED
Abstract
This project is a collaboration between large UK pharmaceutical companies, academia and technology suppliers to generate a structured approach to designing age-appropriate medicines for children and technology for predicting their quality and performance.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
Paediatric medicine is currently a "hot-topic" within the pharmaceutical industry and there is a lot of effort going into developing such medicines for children that are acceptable in terms of taste but also provide the relevant dose and exposure required for such patients. The output will provide a smarter route to developing children’s medicines to reduce costs and time of development by determination of the most appropriate testing strategies that drive formulation design.
Lead Participant | Project Cost | Grant Offer |
---|---|---|
ASTRAZENECA UK LIMITED | £147,777 | £ 73,889 |
  | ||
Participant |
||
GLAXOSMITHKLINE SERVICES UNLIMITED | £141,918 | £ 70,959 |
UNIVERSITY OF BATH | £92,000 | £ 92,000 |
JUNIPER PHARMA SERVICES LIMITED | £100,294 | £ 60,176 |
ASTON UNIVERSITY | £14,520 | £ 14,520 |
UNIVERSITY COLLEGE LONDON | ||
UNIVERSITY OF BIRMINGHAM | £90,704 | £ 90,704 |
UNIVERSITY COLLEGE LONDON | £102,018 | £ 102,018 |
PFIZER LIMITED | £150,469 | £ 75,235 |
ACADEMY OF PHARMACEUTICAL SCIENCES | £6,218 | £ 3,731 |
BRISTOL-MYERS SQUIBB PHARMACEUTICALS LIMITED | £146,742 | £ 73,371 |
People |
ORCID iD |
Zofia Mandziuk (Project Manager) |